JY
STRO icon

Jeff Yass’s Sutro Biopharma STRO Stock Holding History

Jeff Yass’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Sell
8,426
-76,476
-90% -$2.38M ﹤0.01% 11210
2026
Q1 		$2.11M Buy
+84,902
New +$1.53M ﹤0.01% 6055
2025
Q4 		– Sell
-10,359
Closed -$90K – 13579
2025
Q3 		$90K Sell
10,359
-14,162
-58% -$121K ﹤0.01% 11632
2025
Q2 		$175K Buy
24,521
+14,287
+140% +$117K ﹤0.01% 11350
2025
Q1 		$66.6K Buy
10,234
+2,887
+39% +$45.5K ﹤0.01% 11759
2024
Q4 		$135K Sell
7,347
-892
-11% -$27.2K ﹤0.01% 11099
2024
Q3 		$285K Buy
8,239
+1,986
+32% +$77.8K ﹤0.01% 9704
2024
Q2 		$183K Buy
6,253
+1,249
+25% +$49.4K ﹤0.01% 10486
2024
Q1 		$283K Buy
5,004
+1,280
+34% +$56.5K ﹤0.01% 9832
2023
Q4 		$160K Sell
3,724
-8,317
-69% -$264K ﹤0.01% 10910
2023
Q3 		$418K Sell
12,041
-1,457
-11% -$63.5K ﹤0.01% 8649
2023
Q2 		$628K Sell
13,498
-2,286
-14% -$114K ﹤0.01% 7777
2023
Q1 		$729K Buy
+15,784
New +$1M ﹤0.01% 7619
2022
Q4 		– Sell
-1,558
Closed -$86K – 13624
2022
Q3 		$86K Sell
1,558
-527
-25% -$31.2K ﹤0.01% 11820
2022
Q2 		$109K Sell
2,085
-2,205
-51% -$123K ﹤0.01% 11397
2022
Q1 		$353K Buy
4,290
+514
+14% +$48.9K ﹤0.01% 9870
2021
Q4 		$562K Buy
3,776
+838
+29% +$150K ﹤0.01% 8865
2021
Q3 		$555K Sell
2,938
-1,374
-32% -$261K ﹤0.01% 9109
2021
Q2 		$802K Sell
4,312
-2,346
-35% -$459K ﹤0.01% 8369
2021
Q1 		$1.51M Buy
+6,658
New +$1.58M ﹤0.01% 6616

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Jeff Yass's STRO Position: Q2 2026 in Review

Jeff Yass reduced its Sutro Biopharma (STRO) stake by 90% in Q2 2026, selling an estimated $2.38M and leaving 8,426 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #11210.

Jeff Yass first reported a position in STRO in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.11M in Q1 2026. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Jeff Yass held 8,426 shares of Sutro Biopharma worth $280K as of Q2 2026.
  • Jeff Yass sold 76,476 Sutro Biopharma shares in Q2 2026, an estimated $2.38M.
  • Sutro Biopharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11210 holding.
  • Jeff Yass first reported a position in Sutro Biopharma in Q1 2021 and has held it in 20 quarters since.
  • Jeff Yass's Sutro Biopharma position peaked at $2.11M in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.